Longitudinal multi-omic profiling separates persistent from resolving sequelae of breast cancer treatment
- 1Institute for Systems Biology, Seattle, WA 98109, USA
Abstract
Long-term treatment sequelae shape health and quality of life for years after breast cancer, yet why some women develop them and others recover remains unclear. Here we follow 16 women through chemotherapy and for two years afterwards, with patient-reported symptoms, clinical chemistries, plasma proteomics, metabolomics, and gut microbiome profiles collected across eight visits from a pre-treatment baseline. Sequelae differ in their timing, with some resolving as chemotherapy ends, whereas fatigue, memory problems, and gas bloating can persist, and weight gain and joint pain can appear only afterwards. Weight gain over the second year scales with the cumulative duration of endocrine therapy and is steepest in premenopausal women. The women who remain fatigued at two years are distinguished by a second surge in fatigue scores beginning around 12 months post-chemotherapy rather than by a failure to recover, as well as by elevated plasma INHBB and depleted RAB37. INHBB is also elevated in UK Biobank participants reporting chronic, moderate, or severe fatigue, measured on the same platform. In the gut microbiome, Faecalibacterium prausnitzii, a butyrate producer, is depleted in the fatigued group at 24 months post-chemotherapy. Our analysis revealed that post-treatment sequelae follow distinct trajectories, each with its own onset. Markers that track those trajectories point to time windows in which intervention could begin before symptoms become established.
Related
- Longitudinal plasma protein profiling in glioblastoma patients using NULISAseq reveals treatment-associated changes across radiation and chemotherapy
- Persistent prefectural ordering of billed urinary albumin quantification in Japan: a nationwide longitudinal ecological study
- Longitudinal Left Atrial Remodeling With Pharmacological Rhythm Versus Rate Control in Paroxysmal and Persistent Atrial Fibrillation
- Persistent Post-Burn Pruritus Following Antihistamine Initiation: A Retrospective Longitudinal Study at a Single Italian Pediatric Burn Center
- Longitudinal Transcriptomic Analysis Identifies Persistent Immune-Related Signature Associated With Restrictive Left Ventricular Filling Patterns After Heart Transplantation
BibTeX
@misc{noh2026longitudinal,
title = {{Longitudinal multi-omic profiling separates persistent from resolving sequelae of breast cancer treatment}},
author = {H. Noh and M. E. Brunkow and A. V. Carr and N. Quinn-Bohmann and L. Pflieger and S. M. Megrath and D. Burgio and N. Bailey and K. McCormick and L. Hood and T. Brown and C. W. Drescher and S. M. Gibbons and N. D. Price and E. D. Ellis and A. T. Magis and N. Rappaport},
howpublished = {medRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.29.26364331},
url = {https://www.medrxiv.org/content/10.64898/2026.09.29.26364331v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Longitudinal multi-omic profiling separates persistent from resolving sequelae of breast cancer treatment
AU - H. Noh
AU - M. E. Brunkow
AU - A. V. Carr
AU - N. Quinn-Bohmann
AU - L. Pflieger
AU - S. M. Megrath
AU - D. Burgio
AU - N. Bailey
AU - K. McCormick
AU - L. Hood
AU - T. Brown
AU - C. W. Drescher
AU - S. M. Gibbons
AU - N. D. Price
AU - E. D. Ellis
AU - A. T. Magis
AU - N. Rappaport
PY - 2026
DA - 2026/09/29
PB - medRxiv
DO - 10.64898/2026.09.29.26364331
UR - https://www.medrxiv.org/content/10.64898/2026.09.29.26364331v1
AB - Long-term treatment sequelae shape health and quality of life for years after breast cancer, yet why some women develop them and others recover remains unclear. Here we follow 16 women through chemotherapy and for two years afterwards, with patient-reported symptoms, clinical chemistries, plasma proteomics, metabolomics, and gut microbiome profiles collected across eight visits from a pre-treatment baseline. Sequelae differ in their timing, with some resolving as chemotherapy ends, whereas fatigue, memory problems, and gas bloating can persist, and weight gain and joint pain can appear only afterwards. Weight gain over the second year scales with the cumulative duration of endocrine therapy and is steepest in premenopausal women. The women who remain fatigued at two years are distinguished by a second surge in fatigue scores beginning around 12 months post-chemotherapy rather than by a failure to recover, as well as by elevated plasma INHBB and depleted RAB37. INHBB is also elevated in UK Biobank participants reporting chronic, moderate, or severe fatigue, measured on the same platform. In the gut microbiome, Faecalibacterium prausnitzii, a butyrate producer, is depleted in the fatigued group at 24 months post-chemotherapy. Our analysis revealed that post-treatment sequelae follow distinct trajectories, each with its own onset. Markers that track those trajectories point to time windows in which intervention could begin before symptoms become established.
ER -